GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » OptiNose Inc (NAS:OPTN) » Definitions » Book Value per Share

OptiNose (OptiNose) Book Value per Share : $-0.88 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is OptiNose Book Value per Share?

OptiNose's book value per share for the quarter that ended in Mar. 2024 was $-0.88.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of OptiNose was -68.50% per year. The lowest was -68.50% per year. And the median was -68.50% per year.

OptiNose's current price is $1.135. Its book value per share for the quarter that ended in Mar. 2024 was $-0.88. Hence, today's PB Ratio of OptiNose is .

During the past 9 years, the highest P/B Ratio of OptiNose was 35.86. The lowest was 1.74. And the median was 5.73.


OptiNose Book Value per Share Historical Data

The historical data trend for OptiNose's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OptiNose Book Value per Share Chart

OptiNose Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
Get a 7-Day Free Trial Premium Member Only 1.34 0.13 -0.27 -0.51 -0.77

OptiNose Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.66 -0.62 -0.69 -0.77 -0.88

Competitive Comparison of OptiNose's Book Value per Share

For the Drug Manufacturers - Specialty & Generic subindustry, OptiNose's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OptiNose's PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, OptiNose's PB Ratio distribution charts can be found below:

* The bar in red indicates where OptiNose's PB Ratio falls into.



OptiNose Book Value per Share Calculation

OptiNose's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-86.61-0.00)/112.40
=-0.77

OptiNose's Book Value Per Share for the quarter that ended in Mar. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-99.22-0.00)/113.04
=-0.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


OptiNose  (NAS:OPTN) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


OptiNose Book Value per Share Related Terms

Thank you for viewing the detailed overview of OptiNose's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


OptiNose (OptiNose) Business Description

Traded in Other Exchanges
Address
1020 Stony Hill Road, Suite 300, Yardley, PA, USA, 19067
OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms (mcg), a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.
Executives
Marino Michael F Iii officer: Chief Legal Officer & Corp Sec C/O NUPATHE, INC., 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Ramy A Mahmoud officer: President & COO 1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067
Peter K Miller director, officer: Chief Executive Officer C/O INTERNET CAPITAL GROUP, 690 LEE ROAD, SUITE 310, WAYNE PA 19087
Mvm Partners, Llc 10 percent owner OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108
Michele Janis officer: Acting Chief Financial Officer 1020 STONY HILL ROAD, YARDLEY PA 19067
Victor M Clavelli officer: Chief Commercial Officer 1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067
Paul Jr. Spence officer: Chief Commercial Officer 1507 POWNAL DRIVE, YARDLEY PA 19067
Anthony J Krick officer: Chief Accounting Officer 1020 STONY HILL ROAD, YARDLEY PA 19067
R John Fletcher director C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Kyle Dempsey director OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108
Eric Bednarski director OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108
Partners Llp Mvm 10 percent owner 30 ST. GEORGE STREET, LONDON X0 W1S SFH
Keith A. Goldan officer: Chief Financial Officer 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Joseph C Scodari director JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Tomas J. Heyman director C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080